Inactive Instrument

Pharmacyclics, Inc. Share Price

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
21/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
21/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
08/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
05/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
05/03/15	Wall Street closes up slightly ahead of jobs report	RE
05/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
07/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
07/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

05/03/15	Wall Street se reprend un peu dans un climat d'attente
05/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	31/01/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.36%	+0.14%	-0.95%	+14.33%	48.53B
REVOLUTION MEDICINES, INC.	-1.55%	-2.45%	+393.44%	+475.29%	39.87B
IQVIA HOLDINGS INC.	-0.77%	+8.86%	+27.01%	+7.31%	38.68B
BEONE MEDICINES AG	-1.34%	-4.66%	+2.11%	+50.96%	35.13B
CELLTRION, INC.	-2.41%	+2.59%	+11.68%	+41.16%	29.79B
MEDPACE HOLDINGS, INC.	-0.51%	-2.65%	+32.67%	+122.34%	16.11B
ASCENDIS PHARMA A/S	+0.25%	-4.11%	-	-	16.08B
EUROFINS SCIENTIFIC SE	-0.62%	+1.23%	+1.80%	+15.05%	13.61B
ICON PUBLIC LIMITED COMPANY	-3.14%	-7.17%	-4.93%	-37.59%	12.62B
Average	-1.35%	+0.86%	+57.85%	+86.11%	27.82B
Weighted average by Cap.	-1.26%	+1.82%	+75.08%	+105.17%